[WCLC2016]上海市肺科医院展示多项临床研究成果

作者:肿瘤瞭望   日期:2016/12/5 10:29:34  浏览量:23563

肿瘤瞭望版权所有，谢绝任何形式转载，侵犯版权者必予法律追究。

在历届WCLC会议中，今年是中国学者表现最亮眼的一次。上海市肺科医院带来了大量的高质量临床研究，以口头报告、壁报交流的形式展现了研究成果，在Meeting the Expert Session和Scientific Session等专场也有他们的身影。详情如下。

　　在历届WCLC会议中，今年是中国学者表现最亮眼的一次。上海市肺科医院带来了大量的高质量临床研究，以口头报告、壁报交流的形式展现了研究成果，在Meeting the Expert Session和Scientific Session等专场也有他们的身影。详情如下。

 

　　主题报告（Keynote speech）

 

　　周彩存

 

　　讲题：SC05.03 novel tyrosine kinase inhibitors in lung cancer

 

　　专场：SC05: Novel drugs in thoracic cancer

 

　　时间：12月5日11:40-12:00

 

　　地点： C2

 

　　WCLC专场主持（Chair of session）

 

　　周彩存教授在12月7日担任PL04a: Immune checkpoint inhibitors in advanced NSCLC和ED11: Advanced NSCLC:State–of–the–Art Treatment专场的主持。

 

　　专家面对面专场（Meet the expert session）

 

　　李雪飞

 

　　讲题：MET21.01: Next generation sequencing

 

　　专场：Meet the Expert (MTE21)

 

　　时间：12月7日07:30 - 08:30

 

　　地点：Schubert 1

 

　　口头报告（Oral presentation）

 

　　任胜祥

 

　　MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC

 

　　专场：MA04: HER2， P53， KRAS， and other targets in advanced NSCLC

 

　　时间： 12月5日16:12-16:18

 

　　地点：Lehar 3-4

 

　　赵沙

 

　　OA11.07: Combining Apatinib and anti-PD-L1 antibody Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

 

　　专场：OA11: Angiogenesis in advanced lung cancer

 

　　时间：12月6日12:05-12:15

 

　　地点：Stolz 2

 

　　蔡薇菁

 

　　MA15.03: The predictive value of mutation/neoantigen burden from ctDNA on the efficacy of PD-1 blockade in advanced NSCLC

 

　　专场：MA15: Immunotherapy prediction

 

　　时间：12月7日14:32-14:38

 

　　地点： Schubert 1

 

　　壁报交流（Poster presentation）

 

　　周彩存

 

　　●P2.06-013: Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy

 

　　●P3.02b-096: Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results

 

　　李雪飞

 

　　●P3.02b-104: Rebiopsy for patients with non-small cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitors failure

 

　　苏春霞

 

　　●P2.03b-092: Predictive and Prognostic Effect of Circulating Tumor Cells in Non-small cell lung Cancer treated with targeted therapy

 

　　●P1.07–031: Clinical Evaluation of Folate Receptor–Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer

 

　　吴凤英

 

　　●P3.02c–025: Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

 

　　张洁

 

　　●P2.03b–032: The Peculiar Changing Pattern of Serum NSE Acts as an Indicator of Transformation from Adenocarcinoma to SCLC

 

　　倪健

 

　　●P2.05–028: Comparison of Adjuvant Chemotherapy with or without Radiotherapy in NSCLC Patients with Stage IIIA–Single Station N2

 

　　蒋涛

 

　　●P3.02b–075: Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients

 

　　●P3.02b–076: Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases

 

　　●P3.02b–091: Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation

 

　　●P3.02c–049: Dendritic Cells Modified with Tumor–Associated Antigen Gene Demonstrate Enhanced Antitumor Effect against Lung Cancer

 

敬请期待《肿瘤瞭望》的后续报道！

版面编辑：赵丽丽  责任编辑:张彩琴

本内容仅供医学专业人士参考

相关搜索

WCLC 2016上海市肺科医院